Winai Porntipworawech: The $50 Life-Saving Drug Big Pharma Doesn’t Want You to See
Winai Porntipworawech, Former Vice President of GCME, shared a post on LinkedIn:
“Brazilian scientists at Butantan Institute developed a snake venom-derived drug that dissolves dangerous blood clots within minutes without major side effects.
The medication costs $50 per treatment compared to American alternatives charging more than $5,000 with significant bleeding risks.
The drug uses a modified protein from Brazilian pit viper venom that specifically targets clot-forming proteins.
Unlike American blood thinners that affect entire clotting systems, this medication only dissolves existing dangerous clots.
Patients avoid the bleeding complications that kill thousands yearly from traditional treatments.
It works like targeted demolition rather than carpet bombing.
The pharmaceutical industry resistance reveals priorities.
American drug companies promote expensive blood thinners despite high complication rates and limited effectiveness.
The cheap Brazilian alternative threatens $30 billion in yearly American anticoagulant sales.
Critics argue industry lobbying delays FDA approval despite proven safety in extensive Brazilian trials.
For 795,000 Americans suffering strokes yearly and millions taking blood thinners, this represents lifesaving innovation kept inaccessible.
The current American treatment causes 1 in 100 patients to suffer dangerous bleeding episodes.
Brazilian alternatives prevent both clots and complications while costing 100 times less than American medications.
Should American patients suffer dangerous side effects when Brazilian alternatives prove safer and cheaper?
Source: Butantan Institute and New England Journal of Medicine, February 2025.”
Stay updated with Hemostasis Today.
-
Jun 14, 2026, 22:49Cihan Ay: From First Oral Presentation to Pro and Con Debate – A 20-Year EHA Journey
-
Jun 14, 2026, 19:54Tareq Abadl: What Happens If You Transfuse the Wrong Blood Group?
-
Jun 14, 2026, 19:46Amber Yates: Stretching Scientific Muscles in Areas of Hematology – Day 2 at EHA 2026
-
Jun 14, 2026, 19:41Peter Loffelhardt: Thousands of People Coming in – Second Day at EHA 2026
-
Jun 14, 2026, 19:38Jecko Thachil: Can We Predict and Prevent Bleeding in APL?
-
Jun 14, 2026, 19:32Highlights from Day 1 at the EHC Leadership Conference 2026
-
Jun 14, 2026, 18:01Ahmar U. Zaidi: The First Pivotal Study of a New Mechanism in Sickle Cell Disease
-
Jun 14, 2026, 18:00Lennart Lenk: Witnessing Former Boss Deliver a Plenary Talk at EHA 2026
-
Jun 14, 2026, 18:00Priya Sriskandarajah: Great Presentations on Recent Advances in Myelofibrosis at EHA 2026